NOXXON Pharma: Half-Yearly Report on the Liquidity Contract with Invest Securities

BERLIN--()--Regulatory News:

Pursuant to the liquidity contract entrusted to Invest Securities by NOXXON Pharma (Paris:ALNOX), on December 31, 2017 the following assets appeared on the liquidity account:

  • Number of shares: 23,652
  • Cash balance of the liquidity account: €11,792(1)

As a reminder, on 30 June 2017, the following assets appeared in the liquidity account:

  • Number of shares: 12,415
  • Cash balance of the liquidity account: €53,313

(1) Including €75,000 contribution to the assets made in the second half of 2017.

About NOXXON

NOXXON’s oncology-focused pipeline acts on the cancer immunity cycle by breaking the tumor protection barrier, blocking tumor repair and exposing hidden tumor cells. Through neutralizing chemokines in the tumor microenvironment, NOXXON’s approach works in combination with other forms of treatment to weaken tumor defenses against the immune system and enable greater therapeutic impact. Building on extensive clinical experience and safety data, the lead program NOX-A12 will deliver top-line data from a Keytruda® combination trial in metastatic colorectal and pancreatic cancer patients in 2018. Further information can be found at: www.noxxon.com

Keytruda® is a registered trademark of Merck Sharp & Dohme Corp.

https://www.linkedin.com/company/noxxon-pharma-ag

https://twitter.com/noxxon_pharma

Disclaimer

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.

Contacts

NOXXON Pharma

Contacts

NOXXON Pharma